Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone for Prolonged Grief Disorder
NCT04547985Phase 4Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Jan 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of naltrexone in prolonged grief disorder (PGD), sponsored by Weill Cornell Medicine. Started Jan 2021; status: terminated.
02
Drugs
naltrexone
03
Conditions
prolonged grief disorder (PGD)
Beyond the preview
Go deeper on NCT04547985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547985.